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Prediction of liver ﬁbrosis progression by non-invasive tests
in chronic hepatitis C: The impact of validation
To the Editor:
We appreciated the article by Rocco et al. about the prognostic
ability of 13C2-aminopyrine breath test (13C-ABT) to predict liver
ﬁbrosis progression in patients with chronic hepatitis C [1]. The
identiﬁcation of patients with hepatitis C at higher risk of liver
ﬁbrosis progression is clinically relevant in order to preferentially
focus healthcare resources and antiviral treatment, and to target
interventions aimed at preventing end-stage liver complications.
The authors conducted one of the few studies evaluating the
prognostic ability of a non-invasive method for liver ﬁbrosis by
using paired liver biopsies as reference standard with a long-term
follow-up. Importantly, they found that 13C-ABT accurately
predicts the risk of liver ﬁbrosis progression. We believe that this
article deserves several comments.
Rocco et al. refers to image techniques for the non-invasive
assessment of liver ﬁbrosis, such as transient elastography, as
limited by costs, availability and accuracy. However, transient
elastography is a widespread tool for the assessment of liver
ﬁbrosis and its excellent accuracy for the identiﬁcation of cirrho-
sis has been well established by many studies [2]. Transient elas-
tography has also proven to predict 5-year clinical outcomes in
chronic hepatitis C [3].
With respect to serum biomarkers for liver ﬁbrosis, the
authors state that they are not yet widely applied in clinical
practice and they are not recommended by guidelines. How-
ever, serum biomarkers, including AST-to-Platelet Ratio index
(APRI) and Fibrotest-Fibrosure, have shown good performance
in chronic hepatitis C. Moreover, they are able to predict long-
term clinical outcomes in patients with chronic hepatitis C
[3,4]. APRI is an excellent ﬁrst line screening test since it has
virtually no cost and global availability. A recent meta-analysis
indicates that APRI should be regarded as a ﬁrst-line screening
test for liver ﬁbrosis in hepatitis C in countries with limited
healthcare resources, and that more expensive tests should
demonstrate a clear advantage in terms of performance [5].
Guidelines from the European Association for the Study of
the Liver (EASL) have actually recommended the use of serum
biomarkers for the diagnosis of signiﬁcant liver ﬁbrosis in
chronic hepatitis C [6].
Finally, Rocco et al. did not mention three issues that are
important when dealing with non-invasive methods for the diag-
nosis of liver ﬁbrosis: (1) the cost of 13C-ABT as compared to the
other non-invasive methods; (2) the relatively small amount of
validation studies on 13C-ABT as compared to the other tests
(see Table 1); (3) the fact that 13C-ABT is time-consuming
(>2 h) and thus unpractical in the busy clinical setting, as com-
pared to transient elastography (<5 min), APRI and Fibrotest-
Fibrosure.
Considering that both transient elastography and serum bio-
markers have been extensively validated, have proven to predict
clinical outcomes, and have been recommended by guidelines,
we believe that further studies are needed in order to validate
13C-ABT, and to demonstrate a clear advantage in terms of cost
and easy accessibility in clinical practice, as compared to more
widespread non-invasive tools.
We conclude that identiﬁcation of non-invasive tests able to
predict progression of liver ﬁbrosis is of paramount importance
in clinical practice. The choice of the non-invasive method should
rely on its validation, cost, local availability and guidelines.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Table 1. Main validation features of 13C-ABT, APRI, Fibrotest-Fibrosure and transient elastography.
No. of studies 
in HCV
Area under the curve (AUC) 
for prediction of cirrhosis
Recommended by EASL guidelines
13C-ABT 6 0.92-0.95 No
Transient elastography >100 0.90-0.99 Yes
APRI >100 0.61-0.94 Yes
Fibrotest-Fibrosure® >100 0.71-0.87 Yes
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Reply to: ‘‘Prediction of liver ﬁbrosis progression by
non-invasive tests in chronic hepatitis C: The impact of validation’’
To the Editor:
We read with interest the comment by Sebastiani et al. on our
article on the ability of 13C2-aminopyrine breath test (13C-ABT)
to predict the progression of liver ﬁbrosis in patients with hepa-
titis C virus (HCV)-related chronic hepatitis C [1]. They remarked
on the existence of laboratory and instrumental tools [2] other
than 13C-ABT, largely validated and even suggested by current
guidelines [3], in the prediction of severity of HCV-related liver
diseases.
Liver ﬁbrosis, as evaluated on biopsy samples, is of crucial
importance for the diagnosis of severity of liver diseases and is
still the best prognosis predictor in patients with HCV-related
chronic hepatitis [4]. The quest for non-invasive procedures able
to accurately stage liver ﬁbrosis and to predict outcome has led to
various laboratory tests and imaging techniques. However, the
rate and speed of ﬁbrosis progression are highly variable, ranging
from slow to rapid progression, probably in relation to host char-
acteristics, external factors, co-infections and co-morbidities [4].
It is noteworthy that one of the major limitations of the invasive
and non-invasive methods currently available to stage liver ﬁbro-
sis is that none can predict the likelihood of disease progression
at an early stage of the disease.
Transient elastography and serum markers have a high accu-
racy in the diagnosis of liver ﬁbrosis for which they are recom-
mended by current guidelines [3]. However, they have been
proven to predict the outcome of HCV-related chronic disease
only in terms of liver-related complications and survival [5-7].
In contrast, thanks to the experimental design of our study, which
included only HCV-infected patients naïve to therapy, in absence
of liver cirrhosis and other causes of liver disease, who under-
went paired biopsies in a long-term follow-up (mean period
7 years), we were able to demonstrate that the 13C-ABT predicts
the likelihood of disease progression at an early stage of the dis-
ease. Thus, a comparison between the 13C-ABT and the other tests
mentioned by Sebastiani et al. in terms of diagnostic performance
and health costs is not feasible.
Given the rapidly changing therapeutic landscape of HCV-
related chronic diseases, it might become critical to identify
who should be treated now and who might best wait for treat-
ment. Thus, in the near future, the early identiﬁcation of the sub-
group of subjects at higher risk of liver ﬁbrosis progression could
be decisive in allocating healthcare resources and selecting anti-
viral treatment.
In conclusion, with the premise that further studies would be
advisable to further validate 13C-ABT, we believe that this test can
be a useful complementary tool to evaluate the outcome of
patients chronically infected with HCV.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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